Combination of CpG-oligodeoxynucleotides with recombinant ROP2 or GRA4 proteins induces protective immunity against Toxoplasma gondii infection

Sánchez, Vanesa Roxana; Pitkowski, Martín N.; Cuppari, Anahí V. Fernández; Rodríguez, Facundo M.; Fenoy, Ignacio Martín; Frank, Fernanda M.; Goldman, Alejandra; Corral, Ricardo S.; Martin, Valentina

doi:10.1016/j.exppara.2011.04.004

Cited by 40 publications

(23 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Previous studies described a potentiated effect against cyst formation in T. gondii after vaccination with rTgROP2 + rTgROP4, which was not observed after single inoculation of these proteins regardless of the mouse strain employed (Dziadek et al, 2009(Dziadek et al, , 2011(Dziadek et al, , 2012. In contrast, vaccination with rTgROP2, rTgGRA4 and rTgROP2 + rTgGRA4 combination vaccine against T. gondii challenge infection in mice exhibited the same efficacy (Sánchez et al, 2011), supporting our findings concerning the synergistic effect, but only in groups vaccinated with rhoptry proteins.…”

Section: Discussionsupporting

confidence: 90%

“…On the other hand, the highest IL-4 secretion was observed in splenocytes of the group vaccinated with rNcGRA7, according to previous results (Aguado-Martínez et al, 2009;Jiménez-Ruiz et al, 2012), but the average secretion of this cytokine in all other groups was very low. Previous studies on TgROP2-vaccines against T. gondii showed high secretion of IFN-␥, according to our results, although IL-4 levels were also high (Dziadek et al, 2009(Dziadek et al, , 2011(Dziadek et al, , 2012Sánchez et al, 2011). Paradoxically, high levels of IFN-␥ were also detected when TgNTPase-II was employed as vaccine in a mouse model of toxoplasmosis (Tan et al, 2011), whereas our results show the opposite picture.…”

Section: Discussioncontrasting

confidence: 75%

See 1 more Smart Citation

A vaccine formulation combining rhoptry proteins NcROP40 and NcROP2 improves pup survival in a pregnant mouse model of neosporosis

Pastor-Fernández

Arranz-Solís

Regidor‐Cerrillo

et al. 2015

Veterinary Parasitology

View full text Add to dashboard Cite

Section: Discussionsupporting

confidence: 90%

Section: Discussioncontrasting

confidence: 75%

A vaccine formulation combining rhoptry proteins NcROP40 and NcROP2 improves pup survival in a pregnant mouse model of neosporosis

Pastor-Fernández

Arranz-Solís

Regidor‐Cerrillo

et al. 2015

Veterinary Parasitology

View full text Add to dashboard Cite

“…While looking for potentially useful candidate antigens, researchers have also tried to improve the level of immune protection against T. gondii disease through the use of vaccine adjuvants. Such adjuvants include Freund’s, cholera toxin, IL-12 [45], hyaluronidase (HAase) [46] and CpG-oligodeoxynucleotides [47]. …”

Section: Discussionmentioning

confidence: 99%

Identification and characterization of Toxoplasma gondii aspartic protease 1 as a novel vaccine candidate against toxoplasmosis

et al. 2013

View full text Add to dashboard Cite

BackgroundToxoplasma gondii is an obligate intracellular parasite that can pose a serious threat to human health by causing toxoplasmosis. There are no drugs that target the chronic cyst stage of this infection; therefore, development of an effective vaccine would be an important advance. Aspartic proteases play essential roles in the T. gondii lifecycle. The parasite has four aspartic protease encoding genes, which are called toxomepsin 1, 2, 3 and 5 (TgASP1, 2, 3 and 5, respectively).MethodsBioinformatics approaches have enabled us to identify several promising linear-B cell epitopes and potential Th-cell epitopes on TgASP1, thus supporting its potential as a DNA vaccine against toxoplasmosis. We expressed TgASP1 in Escherichia coli and used the purified protein to immunize BALB/c mice. The antibodies obtained were used to determine where TgASP1 was localized in the parasite. We also made a TgASP1 DNA vaccine construct and evaluated it for the level of protection conferred to mice against infection with the virulent RH strain of T. gondii.ResultsTgASP1 appears to be a membrane protein located primarily at the tip of the T. gondii tachyzoite. Investigation of its potential as a DNA vaccine showed that it elicited strong humoral and cellular immune responses in mice, and that these responses were mediated by Th-1 cells. Mice immunized with the vaccine had greater levels of protection against mortality following challenge with T. gondii RH tachyzoites than did those immunized with PBS or the empty vector control.ConclusionsTgASP1 is a novel candidate DNA vaccine that merits further investigation.

show abstract

“…The co-administration of T. gondii recombinant proteins ROP2 and GRA4 with this candidate adjuvant resulted in strong predominant Th1 response manifested as high IgG2a/IgG1 antibody ratio and increased synthesis of IFN-γ. 48 The next promising adjuvants able to expand the vaccine induced-cellular mechanisms are cytokines such as IL-12 and IL-18. Both cytokines skew the immune response toward Th1 pattern and have been shown to be very efficient as components of the experimental anti-Toxoplasma subunit or DNA vaccines.…”

Section: Future Prospectsmentioning

confidence: 99%

Recombinant ROP2, ROP4, GRA4 and SAG1 antigen-cocktails as possible tools for immunoprophylaxis of toxoplasmosis

Dziadek

Brzostek

2012

Bioengineered

View full text Add to dashboard Cite

Toxoplasmosis is a globally distributed foodborne zoonosis caused by a protozoan parasite Toxoplasma gondii. Usually asymptomatic in immunocompetent humans, toxoplasmosis is a serious clinical and veterinary problem often leading to lethal damage in an infected host. In order to overcome the exceptionally strong clinical and socio-economic impact of Toxoplasma infection, the construction of an effective vaccine inducing full immunoprotection against the parasite is an urgent issue. In the last two decades many live attenuated, subunit and DNA-based vaccines against toxoplasmosis have been studied, however only partial protection conferred by vaccination against chronic as well as acute infection has been achieved. Among various immunization strategies, no viable subunit vaccines based on recombinant secretory (ROP2, ROP4 and GRA4) and surface (SAG1) T. gondii proteins have been found as attractive tools for further studies. This is due to their high, but still partial, protective efficacy correlated with the induction of cellular and humoral immune responses.

show abstract

Combination of CpG-oligodeoxynucleotides with recombinant ROP2 or GRA4 proteins induces protective immunity against Toxoplasma gondii infection

Cited by 40 publications

References 40 publications

A vaccine formulation combining rhoptry proteins NcROP40 and NcROP2 improves pup survival in a pregnant mouse model of neosporosis

A vaccine formulation combining rhoptry proteins NcROP40 and NcROP2 improves pup survival in a pregnant mouse model of neosporosis

Identification and characterization of Toxoplasma gondii aspartic protease 1 as a novel vaccine candidate against toxoplasmosis

Recombinant ROP2, ROP4, GRA4 and SAG1 antigen-cocktails as possible tools for immunoprophylaxis of toxoplasmosis

Contact Info

Product

Resources

About